Background theses for the formulation of guidelines on diagnosis and therapy metabolic bone disease as a part of CKD-MBD, with specific focus on low mineral bone content in DXA examinationGuidelines

Palička Vladimír, Sulková Dusilová Sylvie, Brunerová Ludmila

Clin Osteol 2019; 24(4): 169-177

The paper brings the basal background for the interdisciplinary cooperation between clinical osteology and nephro­logy in the field of metabolic osteopathy in kidney patients. Traditionally, renal bone disease is presented as a result of missing excretory, as well as endocrine renal function. Its main cause is secondary hyperparathyroidism, resp. disordered function of parathyroid glands. The term CKD-MBD, promoted in 2006, take into account the association between bone disorder and its systemic consequences, namely cardiovascular. The indication for the DXA assessment in kidney patients is growing. Low bone mineral content, however, is not representative...

Souvislost mezi kostní a cévní kalcifikací: důkazy z klinických studiíReview articles

Szulc Pawel

Clin Osteol 2019; 24(4): 178-190

Densitometry in patients with chronic kidney diseaseReview articles

Brunerová Ludmila

Clin Osteol 2019; 24(4): 192-197

Advanced chronic kidney disease (CKD G3b-5) as CKD-MBD (mineral and bone disorder associated with CKD) is connected with low bone mineral density (BMD) and significantly increased fracture risk (2-100x) that has a significant negative impact on quality of life and prognosis of these patients. Bone histomorphonetry represents the gold standard for diagnostics of CKD-MBD bone disorder subtypes, however, due to several reasons it is performed rarely in clinical practice. Thus, more attention is paid to noninvasive differential diagnostic procedures (DXA, markers of bone turnover). Original 2009 KDIGO (Kidney Disease Improving Global Outcomes) guidelines...

Bone disease in patients after organ transplantationReview articles

Brunová Jana

Clin Osteol 2019; 24(4): 199-203

Organ transplantation is associated with the decrease in bone mass and increased incidence of low-energy fractures, whether in consequence of the previous illness or anti-rejection treatment and post-transplantation complications. All patients after organ transplant should be examined for possible bone involvement and appropriately treated. The basic measures to reduce the bone loss following transplantation primarily include, apart from the general rules for osteoporosis prevention, regulation of calcium phosphate metabolism, vitamin D insufficiency, secondary hyperparathyroidism, and reduction of the cumulative dose of glucocorticoids. Individualized...

Calciphylaxis as a multidisciplinary problem: important information (not only) for clinical osteologists and case reportsCase reports

Sulková Dusilová Sylvie, Šafránek Roman, Pokorná Anita, Soukup Tomáš, Bělobrádková Martina, Horáček Jiří, Bláha Vladimír, Palička Vladimír

Clin Osteol 2019; 24(4): 205-215

Calciphylaxis (CUA -⁠ calcifying uremic arteriolopathy) is a serious clinical complications characterized by large and painful skin and subcutaneous tissue ulcerations and necrosis, associated with the risk of sepsis and mortality. Its pathogenesis is quite complicated. Despite it is a rare entity, physicians of all specialities may meet this disease. Therefore, this paper focuses on principal characteristics of CUA, risk factors in pathogenesis (namely calcium and phosphate metabolism disturbances, hyperparathyroidism, and association with warfarin therapy), as well as on therapeutics principles and possibilities. The most promising current...

ODPORÚČANIE SOMOK DLHODOBÁ LIEČBA OSTEOPORÓZY DENOSUMABOMErrata et corrigenda

MUDr. Vaňuga Peter, PhD.; doc. MUDr. Killinger Zdenko, PhD.; doc. MUDr. Jackuliak Peter, PhD.; Mph; prof. MUDr. Payer Juraj, PhD.; Frcp

Clin Osteol 2019; 24(4): 216-217

První biosimilár k léčbě osteoporózy v EU schválen!Advertorial

Vaněk Martin

Clin Osteol 2019; 24(4): 219-222